Pinchas Cohen
Showing 1–2 of 2 transcripts.
- Milken Institute58 min
Will You Live to a Healthy 100?
Francis Collins, Nir Barzilai, Elizabeth Blackburn, Pinchas Cohen, Joon Yun
A panel of researchers and investors shifts the longevity paradigm from extending chronological lifespan to maximizing healthspan by treating aging as a primary risk factor for chronic disease. Key figures such as Nir Barzilai, Elizabeth Blackburn, and Jun Jung highlighted actionable strategies including genetic insights from centenarians, the management of senescent cells, and the development of a $7 trillion market focused on restoring homeostatic capacity. These efforts are culminating in the imminent TAME clinical trial, which aims to establish aging as an FDA-recognized disease and unlock pharmaceutical investment for drugs like Metformin and Rapamycin to extend human health by two years.
- Milken Institute1h 3m
Longevity Is Opportunity: Riding the Demographic Wave
Pinchas Cohen, Michael Hodin, Dan Houston, Paul Irving, Jody Holtzman, Eric Schmidt
Driven by a historic demographic inversion where the over-60 population now exceeds the under-14 group, the traditional retirement model has collapsed due to extended lifespans outpacing savings and healthcare innovations. This shift has catalyzed a $3.5 trillion market dominated by the over-50 demographic, prompting corporate leaders and investors to pivot from acute care toward prevention, wellness, and extended career engagement strategies. Organizations like BMW and emerging startups such as Neuropath are now adapting workplace structures and diagnostic technologies to address the financial, biological, and social challenges of an aging global workforce.